Concomitant use of sorbitol (Ora-Blend, Ora-Blend SF, Numoisyn Lozenges, Saliva Substitute) with sodium polystyrene sulfonate may cause colonic necrosis. Therefore, use of this combination treatment is not recommended.
Sodium polystyrene sulfonate may decrease the absorption of thyroxine or levothyroxine (Synthroid). Therefore, the administration of thyroid hormones and sodium polystyrene sulfonate should be separated by at least 4 hours.
PREGNANCY: Sodium polystyrene sulfonate is classified asFDA pregnancy risk category C. Use of sodium polystyrene sulfonate during pregnancy has not be adequately studied. Due to the lack of conclusive safety data, sodium polystyrene sulfonate should only be used during pregnancy if the benefits of treatment outweigh the potential risk to the fetus.
NURSING MOTHERS: It is not known if sodium polystyrene sulfonate is excreted in human milk. Due to the lack of safety data, this medication should be used cautiously in females who are breastfeeding.
REFERENCE: FDA Prescribing Information.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.